19411-48-4

Upstream product

• 122-04-3 4-nitro-benzoyl chloride 
• 63-74-1 sulfanilamide 
• 3460-11-5 4-nitrobenzanilide 

Downstream Products

• 4389-05-3 4-amino-N-(4-sulfamoylphenyl)benzamide 
• 346719-87-7 N-(4-nitro-benzoyl)-sulfanilic acid acetylamide 
• 1262334-30-4 2-[(2,6-dichlorophenyl)amino]-N₁-phenylacetoxyacetyl-N₂-(4-nitrobenzoylamino)benzenesulfonamide 
• 1369787-15-4 1-(4-(aminosulfonyl)phenyl)-5-(4-nitrophenyl)-1H-tetrazole 
• 1452583-24-2 N-(4-sulfamoylphenyl)-4-(3,3,6,6-tetramethyl-1,8-dioxo-9-phenyl-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)benzamide 
• 1452583-25-3 4-(9-(4-cyanophenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-26-4 4-(9-(3-cyanophenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-27-5 N-(4-sulfamoylphenyl)-4-(3,3,6,6-tetramethyl-9-(4-nitrophenyl)-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)benzamide 
• 1452583-28-6 N-(4-sulfamoylphenyl)-4-(3,3,6,6-tetramethyl-9-(3-nitrophenyl)-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)benzamide 
• 1452583-29-7 4-(9-(4-fluorophenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-30-0 4-(9-(4-chlorophenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-31-1 4-(9-(4-bromophenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-32-2 4-(9-(4-hydroxyphenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 
• 1452583-33-3 4-(9-(4-methoxyphenyl)-3,3,6,6-tetramethyl-1,8-dioxo-1,2,3,4,5,6,7,8-octahydroacridin-10(9H)-yl)-N-(4-sulfamoylphenyl)benzamide 

Relevant academic research and scientific papers

Amido/ureidosubstituted benzenesulfonamides-isatin conjugates as low nanomolar/subnanomolar inhibitors of the tumor-associated carbonic anhydrase isoform XII

By using a molecular hybridization approach, two series of amido/ureidosubstituted benzenesulfonamides incorporating substituted-isatin moieties were synthesized. The prepared derivatives were in vitro evaluated for their inhibitory activity against human

Microwave assisted synthesis of novel tetrazole/sulfonamide derivatives based on octahydroacridine, xanthene and chromene skeletons as inhibitors of the carbonic anhydrases isoforms I, II, IV and VII

The synthesis of novel tetrazole/sulfonamide derivatives based on octahydroacridine, xanthene and chromene scaffold by using microwave (MW) assisted techniques is reported in this study. These synthesized hybrid compounds were assayed for the inhibition o

Synthesis of novel acridine and bis acridine sulfonamides with effective inhibitory activity against the cytosolic carbonic anhydrase isoforms II and VII

4-Amino-N-(4-sulfamoylphenyl)benzamide was synthesized by reduction of 4-nitro-N-(4-sulfamoylphenyl)benzamide and used to synthesize novel acridine sulfonamide compounds, by a coupling reaction with cyclic-1,3-diketones and aromatic aldehydes. The new com

Novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors

A series of novel 5-substituted 1H-tetrazoles as cyclooxygenase-2 (COX-2) inhibitors was prepared via treatment of various diaryl amides with tetrachlorosilane/sodium azide. All compounds were tested in cyclooxygenase (COX) assays in vitro to determine COX-1 and COX-2 inhibitory potency and selectivity. Tetrazoles contained a methylsulfonyl or sulfonamide group as COX-2 pharmacophore displayed only low inhibitory potency towards COX-2. Most potent compounds showed IC50 values of 6 and 7 μM for COX-2. All compounds showed IC50 values greater 100 μM for COX-1 inhibition.